Top stocks to buy today: Stock recommendations for June 4, 2025
Top stocks to buy today (AI image)
Stock market recommendations:
According to Mehul Kothari, DVP - Technical Research, Anand Rathi Shares and Stock Brokers, Gujarat State Fertilizers & Chemicals (GSFC), Indegene, and Redington are the top stocks to buy today:
GSFC – Positional Buy
Buy near ₹209–₹203 | Stop Loss: ₹180 | Target: ₹260
GSFC has witnessed a falling trendline breakout on the weekly chart, indicating a shift in long-term trend.
The higher high – higher low structure confirms a reversal from the downtrend.
On the daily chart, the stock has reclaimed both 200 DEMA and 200 SMA, reinforcing bullish strength. Weekly RSI is also on the verge of a breakout, hinting at further momentum.
INDEGENE – Breakout Candidate
Buy near ₹625 | Stop Loss: ₹580 | Target: ₹700
Recently listed Indegene gave a trendline breakout in today's session. The breakout also resembles a bullish flag pattern, a classic continuation setup.
The move was accompanied by a noticeable rise in volumes, suggesting fresh buying interest and potential for follow-through.
REDINGTON – Pullback Buy
Buy near ₹268 | Stop Loss: ₹255 | Target: ₹294
In the first half of May 2025, Redington gave a major breakout above ₹265, followed by a brief rally. The stock has now retested the breakout zone, and turned around after an exact 38.2% Fibonacci retracement of the previous move.
A bullish engulfing candlestick on the daily chart supports the case for a renewed upside.
Stay informed with the latest
business
news, updates on
bank holidays
and
public holidays
.
AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 days ago
- Time of India
Gold price prediction today: What's the gold rate outlook for June 6, 2025
Gold price prediction today: Gold prices have been rising, but are also below their record low. Gold rate rise is showing signs of exhaustion. Where are MCX Gold prices headed and what should investors do? Should they buy or sell gold? Here's the analysis from Jateen Trivedi, VP Research Analyst - Commodity and Currency, LKP Securities: Gold Market Overview MCX Gold June 2025 contract is expected to open slightly higher around ₹98200 levels on Friday, following mixed global cues. Tired of too many ads? go ad free now However, the 30-minute chart reveals critical resistance zones that suggest any upward move should be viewed as a selling opportunity. The precious metal's recent price action indicates exhaustion at higher levels, creating an ideal setup for contrarian traders. Technical Analysis: 30-Minute Timeframe Current Market Structure: Gold has been trading in a volatile range with clear signs of distribution near the ₹99000 psychological level. The recent sharp decline from highs of ₹99300 followed by a recovery attempt suggests a classic bear flag formation. Key Technical Parameters: Expected Opening: ₹98200 (marginally higher) EMA 21: ₹98300 (acting as immediate resistance) EMA 8: ₹97980 (short-term support) RSI (14): Currently at 38.63 (oversold bounce territory) MACD: Showing bearish momentum with histogram in negative territory Bollinger Bands: Price testing middle band with upper band acting as strong resistance Primary Strategy: Sell on Rise Near ₹98500 Strategic Foundation: The ₹98500 level represents a confluence of multiple resistance factors that make it an optimal selling zone: 1. Fibonacci Retracement: 38.2% retracement of the recent decline from ₹99300 to ₹97500 2. Previous Support Turned Resistance: Earlier support level now acting as resistance 3. Bollinger Band Resistance: Approaching the upper band of the current range 4. Volume Profile: Low volume acceptance above ₹98400 levels 5. Psychological Resistance: Round number significance Entry Parameters: Primary Sell Zone: ₹98450-98550 Optimal Entry: ₹98500 Stop Loss: ₹98750 (above recent swing high) Target 1: ₹98000 (immediate support) Target 2: ₹97750 (next significant support) Intraday Execution: Allow initial volatility to settle Watch for any upward movement toward resistance zone Prepare for entry as price approaches ₹98450 Market Sentiment Factors Supporting Bearish View: Technical Breakdown: Clear break below previous support levels Volume Pattern: Higher volume on declines compared to advances Global Headwinds: Strength in Dollar Index pressuring gold Risk Factors: Geopolitical Tensions: Unexpected safe-haven demand Dollar Weakness: Any sudden USD decline Economic Data: Weak US economic indicators Alternative Scenarios Bull Case (Low Probability): If gold sustains above ₹98750 with strong volume, it could target: ₹99000 (psychological resistance) ₹99300 (previous high) Trading Psychology The expected higher opening might create false optimism among retail traders. Professional traders should use this sentiment against the crowd by selling into strength. The key is patience – wait for the right technical setup at the resistance zone. Conclusion The technical setup presents a high-probability selling opportunity near ₹98500. The confluence of resistance factors, combined with bearish momentum indicators, supports the sell-on-rise strategy. However, traders must remain disciplined and execute the plan systematically while maintaining strict risk management protocols. (Disclaimer: Recommendations and views on the stock market and other asset classes given by experts are their own. These opinions do not represent the views of The Times of India)
Economic Times
3 days ago
- Economic Times
Sunil Singhania picks stake in Indegene, stock up 4%
Indegene shares: Sunil Singhania's fund acquired a stake in the company via a significant block deal. Synopsis Indegene shares: Abakkus was one of several institutional investors that participated in the transaction through which private equity giant Carlyle Group fully exited its 10.2% stake in the digital healthcare company. Shares of Indegene Ltd rose as much as 3.7% to Rs 611.50 on the BSE on Thursday, a day after Sunil Singhania's Abakkus Emerging Opportunities Fund picked up a stake in the company through a large block deal. Abakkus was among several institutional investors that bought shares in the transaction where private equity major Carlyle Group exited its entire 10.2% holding in the digital healthcare firm. ADVERTISEMENT A total of 2.53 crore shares, amounting to 10.56% of Indegene's equity, changed hands on Wednesday, June 4, at an average price of Rs 591 apiece, according to exchange data released Thursday. Carlyle, through its unit CA Dawn Investments, was the sole seller in the deal, garnering Rs 1,447 crore from the divestment. Alongside Abakkus, other buyers included East Bridge Capital Master Fund, Societe Generale, Smallcap World Fund, and Premji Invest's affiliate PI Opportunities AIF V. Together, these investors picked up 1.06 crore shares, or 4.42% stake, for Rs 627 crore. The shares were acquired in the price range of Rs 591–591.48 each. Details of other buyers were not available on the National Stock Exchange as of exit marks the end of a four-year investment in Indegene. The global private equity firm had invested $122 million (Rs 917 crore) in April 2021, purchasing 4.55 crore shares at Rs 201 apiece. ADVERTISEMENT Since then, it has sold shares in phases, first during Indegene's IPO in May 2024 at Rs 452 apiece, then at Rs 618 in December 2024, and finally at around Rs 591 this week. The investment delivered an internal rate of return of 31% for Carlyle, underscoring the strong returns possible in India's digital healthcare shares had fallen 4.07% on Wednesday to Rs 594.50 following the block transaction, but rebounded on Thursday as investor interest in the stock remained firm. ADVERTISEMENT Also read | Carlyle group exits Indegene; sells 10.2% stake for Rs 1,447 crore (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel) Nikita Papers IPO opens on May 27, price band set at Rs 95-104 per share Nikita Papers IPO opens on May 27, price band set at Rs 95-104 per share Why gold prices could surpass $4,000: JP Morgan's bullish outlook explained Why gold prices could surpass $4,000: JP Morgan's bullish outlook explained Cyient shares fall over 9% after Q4 profit declines, core business underperforms Cyient shares fall over 9% after Q4 profit declines, core business underperforms L&T Technology Services shares slide 7% after Q4 profit dips L&T Technology Services shares slide 7% after Q4 profit dips Trump-Powell standoff puts U.S. Rate policy in crosshairs: Who will blink first? Trump-Powell standoff puts U.S. Rate policy in crosshairs: Who will blink first? SEBI warns of securities market frauds via YouTube, Facebook, X and more SEBI warns of securities market frauds via YouTube, Facebook, X and more API Trading for All: Pi42 CTO Satish Mishra on How Pi42 is Empowering Retail Traders API Trading for All: Pi42 CTO Satish Mishra on How Pi42 is Empowering Retail Traders Security, transparency, and innovation: What sets Pi42 apart in crypto trading Security, transparency, and innovation: What sets Pi42 apart in crypto trading Bitcoin, Ethereum, or Altcoins? How investors are structuring their crypto portfolios, Avinash Shekhar explains Bitcoin, Ethereum, or Altcoins? How investors are structuring their crypto portfolios, Avinash Shekhar explains The rise of Crypto Futures in India: Leverage, tax efficiency, and market maturity, Avinash Shekhar of Pi42 explains NEXT STORY
Time of India
3 days ago
- Time of India
Sunil Singhania picks stake in Indegene, stock up 4%
Shares of Indegene Ltd rose as much as 3.7% to Rs 611.50 on the BSE on Thursday, a day after Sunil Singhania 's Abakkus Emerging Opportunities Fund picked up a stake in the company through a large block deal. Abakkus was among several institutional investors that bought shares in the transaction where private equity major Carlyle Group exited its entire 10.2% holding in the digital healthcare firm. A total of 2.53 crore shares, amounting to 10.56% of Indegene's equity, changed hands on Wednesday, June 4, at an average price of Rs 591 apiece, according to exchange data released Thursday. Carlyle, through its unit CA Dawn Investments, was the sole seller in the deal, garnering Rs 1,447 crore from the divestment. Who bought? Alongside Abakkus, other buyers included East Bridge Capital Master Fund, Societe Generale, Smallcap World Fund, and Premji Invest's affiliate PI Opportunities AIF V. Together, these investors picked up 1.06 crore shares, or 4.42% stake, for Rs 627 crore. The shares were acquired in the price range of Rs 591–591.48 each. Details of other buyers were not available on the National Stock Exchange as of Thursday. Carlyle's phased exit Carlyle's exit marks the end of a four-year investment in Indegene. The global private equity firm had invested $122 million (Rs 917 crore) in April 2021, purchasing 4.55 crore shares at Rs 201 apiece. Since then, it has sold shares in phases, first during Indegene's IPO in May 2024 at Rs 452 apiece, then at Rs 618 in December 2024, and finally at around Rs 591 this week. The investment delivered an internal rate of return of 31% for Carlyle, underscoring the strong returns possible in India's digital healthcare sector. Indegene's shares had fallen 4.07% on Wednesday to Rs 594.50 following the block transaction, but rebounded on Thursday as investor interest in the stock remained firm. Also read | Carlyle group exits Indegene; sells 10.2% stake for Rs 1,447 crore ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
